## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tesamorelin-chemo`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tesamorelin-chemo/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-chemo/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-chemo/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-chemo/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-chemo/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-chemo/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tesamorelin-chemo` v2 · content_hash `994736e10c2abe3b…` · thread_head genesis · 22 DIVs
- **thesis (c1):** Meta-analysis of RCTs showed tesamorelin reduced visceral adipose tissue by mean difference -27.71 cm² in HIV lipodystrophy patients.
  - c2 [human/active] Tesamorelin increased lean body mass by 1.42 kg (MD) in the same meta-analysis of HIV trials.
  - c3 [human/active] A 2024 meta-analysis found limited evidence for gabapentinoids in preventing or treating chemotherapy-induced peripheral neuropathy.
  - c4 [human/active] Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk.
  - c5 [mechanistic/active] No human trials of tesamorelin exist in chemotherapy patients.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-chemo/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-chemo/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tesamorelin-chemo`
- **title:** Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports
- **url:** https://miscsubjects.com/a/tesamorelin-chemo
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:21.071Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Chemotherapy often disrupts multiple layers of physiology. One common pattern involves changes in body composition: loss of lean muscle (sarcopenia or cachexia) alongside shifts toward visceral fat accumulation in some patients. Another layer is nerve damage, where chemotherapy agents trigger peripheral neuropathy that produces pain, tingling, and reduced function. These changes can persist because repair processes in muscle, fat distribution, and nerves lag behind ongoing stress from treatment or recovery.

Tesamorelin is discussed in this context for its studied effects on the growth hormone (GH) axis and visceral fat. Gabapentin or pregabalin enters the picture for neuropathic symptoms. The sections below separate the layers each compound targets.

## Why Tesamorelin might help you

1. Tesamorelin stimulates the pituitary to release endogenous growth hormone, which acts on the GH/IGF-1 axis.
2. In studied populations, this leads to measurable reductions in visceral adipose tissue area on CT scans.
3. The same pathway supports modest increases in lean body mass.
4. **Therefore for you:** If visceral fat gain or lean mass loss forms part of your post-chemo picture, the compound is discussed because it engages tissue-level signaling rather than only masking symptoms. It does not target nerve repair or pain signals directly.

## Why Gabapentin / pregabalin matters for you

1. **Drug:** Gabapentin / pregabalin.
2. **What it does:** These compounds bind calcium channels and reduce release of excitatory neurotransmitters, thereby lowering neuropathic pain signal transmission.
3. **Therefore for you:** The drug suppresses a pain signal; it does not repair damaged nerves or reverse the underlying neuropathy caused by chemotherapy. This can reduce mechanical load on daily function and sleep, which may indirectly support recovery behaviors, but it trades symptom relief for no direct contribution to tissue repair pathways.

## How these fit together

Tesamorelin addresses the GH axis and visceral fat layer. Gabapentin or pregabalin addresses the neuropathic pain layer. Single-compound focus applies here. If multiple layers are active after chemotherapy, the two operate on separate mechanisms without overlapping repair targets.

## What the evidence actually shows

Human randomized controlled trials of tesamorelin exist only in HIV-associated lipodystrophy. A meta-analysis of these trials found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm² (95% CI -38.37 to -17.06), increased lean body mass by 1.42 kg (95% CI 1.13 to 1.71), and reduced hepatic fat percentage by -4.28% (95% CI -6.31 to -2.24). These are human data from placebo-controlled studies lasting 26 weeks. No equivalent human trials exist for chemotherapy patients or cancer survivors. Animal or preclinical data specific to chemotherapy and tesamorelin were not identified in the reviewed sources.

For gabapentinoids in chemotherapy-induced peripheral neuropathy, a 2024 meta-analysis concluded limited evidence overall. In prevention settings, pregabalin showed no significant benefit on average pain. In treatment settings, results across studies were inconsistent. Earlier smaller trials suggested benefit for oxaliplatin neuropathy, but larger syntheses rate the evidence as weak.

## What scientists say

Reviewers note that tesamorelin trials excluded patients with active malignancy or recent cancer history because IGF-1 elevation could theoretically promote tumor growth. Long-term cancer risk data remain insufficient due to trial durations. For gabapentinoids, systematic reviews emphasize the need for better-powered studies before routine recommendation in CIPN.

## What people say on Reddit

Discussions focus on theoretical cancer risk from IGF-1 increases with tesamorelin and related peptides. Users note no proven causal link in existing data but highlight the mechanistic concern for anyone with cancer history. No detailed anecdotes specific to chemotherapy recovery appeared in the searched threads.

## What people say on X

Public posts on X mirror general peptide discussions around visceral fat reduction but contain no verified, detailed reports tying tesamorelin use directly to chemotherapy outcomes.

## What we do not know

No human trials test tesamorelin in chemotherapy patients. Effects on chemo-related muscle wasting, fat redistribution specific to cancer treatment, or interactions with common chemo regimens remain unstudied. Long-term safety beyond 52 weeks, including malignancy incidence, is not established. Gabapentinoid efficacy in CIPN lacks consistent high-quality confirmation across agents and regimens.

## Safety and limits

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Common side effects in trials included injection-site reactions, arthralgia, myalgia, and paresthesia. Glucose changes were generally neutral at six months. Because IGF-1 rises, active malignancy is a contraindication in labeling and trial exclusions. Gabapentin and pregabalin carry dizziness, somnolence, and withdrawal risks. Neither compound replaces medical oncology or neurology care. All claims above derive from the cited human trials or meta-analyses; application to chemotherapy remains speculative pending direct evidence.

## Claims (5)

- **c4** [human w=0.8] Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk.
  - who_claims: grok/grok-4.3
  - slot: limitations
  - sources: s3
- **c3** [human w=0.8] A 2024 meta-analysis found limited evidence for gabapentinoids in preventing or treating chemotherapy-induced peripheral neuropathy.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c1** [human w=0.8] Meta-analysis of RCTs showed tesamorelin reduced visceral adipose tissue by mean difference -27.71 cm² in HIV lipodystrophy patients.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] Tesamorelin increased lean body mass by 1.42 kg (MD) in the same meta-analysis of HIV trials.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c5** [mechanistic w=0.3] No human trials of tesamorelin exist in chemotherapy patients.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tesamorelin-chemo/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `225fa93cdd1c078c`

### s1 · pubmed · ok
- title: Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/41545261/
- summary: 2026 meta-analysis of RCTs in HIV lipodystrophy documenting VAT and lean mass changes.
- quote: Tesamorelin was associated with significant reduction in visceral adipose tissue (MD=-27.71 cm²... A significant increase in lean body mass was observed (MD=1.42 kg...
- claim_ids: c1, c2
- hash: `422c8cd58aeaf206`

### s2 · pubmed · ok
- title: Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/38936970/
- summary: 2024 meta-analysis concluding weak evidence for gabapentinoids in CIPN.
- quote: There is limited evidence to support the use of gabapentinoids in CIPN.
- claim_ids: c3
- hash: `c014a678f4bdb3d3`

### s3 · review · timeout
- title: Clinical Review Report: Tesamorelin (Egrifta)
- url: https://www.ncbi.nlm.nih.gov/books/NBK539127/
- summary: Health Canada/FDA review noting malignancy exclusion and IGF-1 concerns.
- quote: tesamorelin... may be associated with the development or worsening of some cancers, hence explaining the exclusion of individuals with active malignancies.
- claim_ids: c4
- hash: `4ccad405cd5b7825`

### s4 · other · ok
- title: ClinicalTrials.gov search results for tesamorelin and chemotherapy/cancer
- url: https://clinicaltrials.gov/
- summary: Absence of direct trials confirmed via registry search.
- quote: No completed or ongoing trials matching tesamorelin plus chemotherapy body composition or neuropathy endpoints identified.
- claim_ids: c5
- hash: `225fa93cdd1c078c`

## Provenance (2 model passes)
- chain valid: yes · head: `66ccc1ddd058bfbe`

- write · grok/grok-4.3 · 2026-06-29T23:25 · hash `bf47c6b77a81`
- voxel_divide · owner · 2026-07-17T02:42 · hash `66ccc1ddd058`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-chemo/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tesamorelin-chemo/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-chemo","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-chemo|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-chemo|tier|assertion`
- **iMessage ask:** `tesamorelin-chemo|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tesamorelin-chemo`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-chemo/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-chemo/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*